Salix Pharmaceuticals CEO Carolyn Logan said on a conference call with analysts Thursday that a federal investigation into the Raleigh's company's sales practices could "go on for quite some time."
"It's usually not a short process, as we've been told," she said.
Salix announced last month that it has received a subpoena from the U.S. Attorney's Office for the Southern District of New York requesting documents related to the company's sales and promotional practices for three of its drugs.
The company received the subpoena on Feb. 1, according to its regulatory filing.
The drugs involved are Salix's best-selling Xifaxan, as well as Relistor and Apriso.
Salix said in its filing that it is in the process of responding to the subpoena and intends to cooperate fully with the investigation.